Document Detail


Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
MedLine Citation:
PMID:  17170610     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Severe hypertension is difficult to control. This prospective, randomized, double-blind, active-controlled, multicenter trial compared efficacy and safety of once-daily irbesartan/hydrochlorothiazide (HCTZ) combination therapy with irbesartan monotherapy in severe hypertension. Patients who were untreated or uncontrolled on monotherapy (seated diastolic blood pressure [BP] > or =110 mm Hg) received fixed-dose irbesartan 150 mg/HCTZ 12.5 mg combination therapy for 7 weeks, force-titrated to irbesartan 300 mg/HCTZ 25 mg at week 1 (n=468); or irbesartan 150 mg monotherapy, force-titrated to 300 mg at week 1 (n=269). Significantly more patients on combination therapy achieved seated diastolic BP <90 mm Hg at week 5 (primary end point) compared with monotherapy recipients (47.2% vs 33.2%; P=.0005). Likewise, significantly more patients attained goals per the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (<140/90 mm Hg) at week 5 (34.6% vs 19.2%, respectively; P<.0001), while the mean difference between combination and monotherapy in seated diastolic BP and seated systolic BP was 4.7 mm Hg and 9.7 mm Hg (P<.0001). Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects.
Authors:
Joel M Neutel; Stanley S Franklin; Suzanne Oparil; Amitabha Bhaumik; Agata Ptaszynska; Pablo Lapuerta
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  8     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-15     Completed Date:  2007-01-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  850-7; quiz 858-9     Citation Subset:  IM    
Affiliation:
Orange County Heart Institute and Research Center, 14351 Myford Road, Tustin, CA 92780, USA. jmneutel@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antihypertensive Agents / administration & dosage*,  adverse effects
Biphenyl Compounds / administration & dosage*,  adverse effects
Blood Pressure
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide / administration & dosage*,  adverse effects
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Tetrazoles / administration & dosage*,  adverse effects
Treatment Outcome
United States
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Tetrazoles; 138402-11-6/irbesartan; 58-93-5/Hydrochlorothiazide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
Next Document:  Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment ...